Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

Decera Clinical Education Oncology Podcast · Nov 9, 2021 · 13m

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:

Mechanisms of acquired resistance to TRK inhibitor therapy

Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib

Safety profiles of first- vs second-generation TRK inhibitors

Presenters:

George D. Demetri, MD

Professor of Medicine

Harvard Medical School

Harvard…